A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer’s disease. The company was incorporated in 2019 and is based in San Diego, California.
Financial Summary
| Share Statistics | ADRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,134.7 | $249.2 | 55% |
|
| Shares Out (Mil) | 11.3 | 53.9 | 22% |
|
| Institutional Ownership | 20.1% | 93.0% | 10% |
|
| Float (Mil) | 46.1 | 41.4 | 45% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 1,474 | 631 | 76% |
|
| Price Change (52-week) |
na | 49.2% | na |
|
| Growth | ADRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ADRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $6 | $37 | 7% |
|
| Net Income (TTM) (Mil) | ($88) | ($44) | 12% |
|
| EPS (TTM) | ($7.740) | ($1.600) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($88) | ($33) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($7) | $2 | 32% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 25% |
|
| Enterprise Value (Q1) (Mil) | $2,127 | $175 | 50% |
|
| Valuation | ADRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.42 | na |
|
| P/E | na | 19.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ADRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (38.5%) | (47.7%) | 14% |
|
| ROE | 70.0% | (54.6%) | 95% |
|
| Liabilities to Assets | 76.6% | 29.3% | 72% |
|
| F-Score | 1 | 3 | na |
|
ADARx Pharmaceuticals, Inc. did not pass any screens on 10/5/2026.
